without uremia, of the indiopathic type or that due to
lupus erythematosus 11. Gastrointestinal Diseases: Ulcerative colitis,
regional enteritis 12. Nervous System: Acute exacerbations of multiple
sclerosis, etc. It is also indicated for the treatment of terminal cancer,
organ transplantation, cardiovascular condition etc.

Dosage and administration : It is depending on the specific disease entity being
treated in the following conditions :

Indications

Dosage

Adjunctive
therapy in life-threatening

conditions

Administer 30
mg/kg IV over a period of at least 30 minutes. Dose may be
repeated every 4 to 6 hours for up to
48 hours.

Acute
respiratory distress syndrome (ARDS)

Initially
2-3mg/kg/day IV, decreasing after 7 days.

Rheumatic
disorders unresponsive to standard

therapy (or
during exacerbation episodes).

Administer
either regimen as IV pulse dosing over at least 30 minutes. The regimen may
be repeated if

improvement has
not occurred within a week after therapy. 1 g/day for 1 to 4 days, or 1
g/month for 6 months.

Systemic Lupus
Erythematosus (SLE) unresponsive

to standard
therapy (or during exacerbation episodes).

Administer 1
g/day for 3 days as IV pulse dosing over at least 30 minutes. The
regimen may be

repeated if
improvement has not occurred within a week after therapy, or as the patient's
condition dictates.

Multiple
sclerosis unresponsive to standard

therapy (or
during exacerbation episodes).

Administer 1
g/day for 3 or 5 days as IV pulse dosing over at least 30 minutes. The
regimen may be

repeated if
improvement has not occurred within a week after therapy, or as the patient's
condition dictates.

Administer
either regimen as IV pulse dosing over at least 30 minutes. The regimen may
be repeated if

improvement has
not occurred within 1 week after therapy, or as the patient's condition
dictates. 30

mg/kg every
other day for 4 days or 1 g/day for 3, 5 or 7 days.

Pemphigus &
Bullous Pemphigoid

Administer
either regimen as IV pulse dosing over at least 30 minutes. The regimen may
be repeated if

improvement has
not occurred within 1 week after therapy, or as the patient's condition
dictates. 30

mg/kg every
other day for 4 days or 1 g/day for 3, 5 or 7 days.

In other
indications

Initial dosage
will vary from 10 to 500 mg depending on the clinical problem being treated. The

larger dosage
may be required for short-term management of severe, acute conditions. The
initial dose

should be given
intravenously over a period of at least 5 minutes (e.g up to 250mg) to at
least 30 minutes

(e.g doses
exceeding 250mg). Subsequent doses may be given intravenously or
intramuscularly at

intervals
dictated by the patients response and clinical conditions.

Dosage may be
reduced for infants and children but should be governed more by the severity of
the condition and response of the patient than by age or size. It should not be
less than 0.5mg/kg every 24 hours. Dosage must be decreased or discontinued
gradually when the drug has been administered for more than a few days. Or, as
directed by the registered physicians.

Use in Pregnancy & Lactation : Pregnancy Category C. There are no adequate
and well-controlled studies in pregnant women. It should be used during
pregnancy only if the potential benefit justifies the potential risk to the
fetus. It is not known whether this medicine is excreted in human milk. Caution
should be exercised when this medicine is administered to a nursing woman.